Published in Semin Oncol on December 12, 2013
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 | NCT01449461
Vandetanib in Advanced NSCLC With RET Rearrangement | NCT01823068
Ponatinib in Advanced NSCLC w/ RET Translocations | NCT01813734
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer | NCT01233687
A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | NCT01039948
Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer | NCT01861197
A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants (Chime) | NCT01900652
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov (2015) 1.64
PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival. Oncotarget (2015) 0.97
RET fusion as a novel driver of medullary thyroid carcinoma. J Clin Endocrinol Metab (2014) 0.87
The management of brain metastases in non-small cell lung cancer. Front Oncol (2014) 0.85
Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. Mol Aspects Med (2015) 0.81
Defining a standard set of patient-centred outcomes for lung cancer. Eur Respir J (2016) 0.81
Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. Cancer Immunol Res (2015) 0.80
Mechanisms of tumor-promoting activities of nicotine in lung cancer: synergistic effects of cell membrane and mitochondrial nicotinic acetylcholine receptors. BMC Cancer (2015) 0.80
ErbB2-intronic microRNA-4728: a novel tumor suppressor and antagonist of oncogenic MAPK signaling. Cell Death Dis (2015) 0.79
Targeting lung cancer through inhibition of checkpoint kinases. Front Genet (2015) 0.79
Expression of EGFR and molecules downstream to PI3K/Akt, Raf-1-MEK-1-MAP (Erk1/2), and JAK (STAT3) pathways in invasive lung adenocarcinomas resected at a single institution. Anal Cell Pathol (Amst) (2014) 0.78
Human Genetic Relevance and Potent Antitumor Activity of Heat Shock Protein 90 Inhibition in Canine Lung Adenocarcinoma Cell Lines. PLoS One (2015) 0.78
Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features. Onco Targets Ther (2015) 0.77
Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line. Onco Targets Ther (2015) 0.75
Tumour biomarkers: homeostasis as a novel prognostic indicator. Open Biol (2016) 0.75
Molecular Profiling of Circulating Tumour Cells Identifies Notch1 as a Principal Regulator in Advanced Non-Small Cell Lung Cancer. Sci Rep (2016) 0.75
Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation. Cell Biol Toxicol (2016) 0.75
Resistance to RET-inhibition in RET-rearranged NSCLC is mediated by reactivation of RAS/MAPK signaling. Mol Cancer Ther (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med (2002) 24.87
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol (2007) 18.32
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 17.30
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science (2002) 14.20
Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev (2010) 12.60
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 8.67
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med (2010) 8.59
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med (2012) 8.41
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res (2004) 7.76
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res (2009) 7.35
Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer (2010) 6.81
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med (2012) 6.77
RET, ROS1 and ALK fusions in lung cancer. Nat Med (2012) 6.76
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res (2008) 6.71
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science (1985) 6.56
Targeting MET in cancer: rationale and progress. Nat Rev Cancer (2012) 6.43
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res (2012) 6.23
Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell (2012) 6.09
A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature (1986) 5.88
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res (2007) 5.63
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 5.21
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol (2012) 5.16
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res (2010) 4.70
Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res (2002) 4.46
KIF5B-RET fusions in lung adenocarcinoma. Nat Med (2012) 4.38
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol (2013) 4.30
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res (2005) 4.25
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res (2011) 4.22
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist (2009) 3.92
The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res (2012) 3.80
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell (2006) 3.73
RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol (2012) 3.72
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res (2008) 3.70
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov (2013) 3.64
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol (2011) 3.55
Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med (2013) 3.42
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2005) 3.40
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One (2011) 3.23
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J (1996) 3.22
K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med (1990) 3.16
Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov (2013) 3.13
Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res (2006) 3.12
Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science (1984) 2.97
Neurotrophin signalling in health and disease. Clin Sci (Lond) (2006) 2.85
Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science (1995) 2.83
Retracted Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol (2009) 2.75
Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol (2013) 2.73
Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol (2010) 2.72
Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res (2008) 2.71
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol (2011) 2.69
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res (2012) 2.66
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med (2013) 2.65
Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res (2012) 2.53
Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol (2011) 2.50
Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res (2002) 2.48
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol (2011) 2.44
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol (2013) 2.41
Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol (2013) 2.40
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol (2004) 2.27
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A (1999) 2.22
The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci (2004) 2.19
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 2.19
Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One (2011) 2.17
Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A (1987) 2.11
Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J Clin Oncol (2002) 2.10
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther (2011) 1.98
Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res (2013) 1.94
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci (2008) 1.88
Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol (2009) 1.81
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.79
The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta (2008) 1.77
MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol (2008) 1.74
Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res (2012) 1.71
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol (2013) 1.66
Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res (2006) 1.58
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res (2013) 1.51
ALKoma: a cancer subtype with a shared target. Cancer Discov (2012) 1.50